<SEC-DOCUMENT>0001193125-17-243267.txt : 20170801
<SEC-HEADER>0001193125-17-243267.hdr.sgml : 20170801
<ACCEPTANCE-DATETIME>20170801080935
ACCESSION NUMBER:		0001193125-17-243267
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170801
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170801
DATE AS OF CHANGE:		20170801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		17995047

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d434912d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D. C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): August&nbsp;1, 2017 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>PRECIPIO, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36439</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>91-1789357</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State of Incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4 Science Park, New Haven, CT 06511 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(203) 787-7888 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name, former address and former fiscal year, if changed since last report date) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the
Securities Exchange Act of 1934. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;1, 2017, Precipio, Inc. (the
&#147;<U>Company</U>&#148;) filed a preliminary prospectus supplement to the base prospectus included in the Company&#146;s shelf registration statement on Form&nbsp;S-3 (No.&nbsp;333-201907), filed with the Securities and Exchange Commission (the
&#147;SEC&#148;) on February&nbsp;6, 2015 and declared effective by the SEC on February&nbsp;13, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Current
Report on Form&nbsp;8-K furnished under this Item&nbsp;7.01 shall not be deemed &#147;filed&#148; for any purpose, including for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or
otherwise subject to the liabilities of that Section. Furthermore, the information in this Current Report on Form&nbsp;8-K furnished under this Item&nbsp;7.01 shall not be deemed incorporated by reference into any filing under the Securities Act of
1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company is filing information for the purpose of
updating the description of its business included under the heading, &#147;Item 1. Business&#148; in the Company&#146;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016, filed with the SEC on April&nbsp;13, 2017.&nbsp;The
updated description is filed herewith as Exhibit&nbsp;99.2 and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exh</B>i<B>bits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Precipio, Inc. dated August 1, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Business Update</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PRECIPIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ilan Danieli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ilan Danieli</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;1, 2017</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d434912dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g434912g0731133059618.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECIPIO ANNOUNCES PROPOSED PUBLIC OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEW HAVEN, Conn., (August 1, 2017) &#150; </B>Precipio, Inc. (NASDAQ: PRPO), today announced that it intends to offer for sale its common stock and
warrants in an underwritten public offering. The Company intends to use the net proceeds from this offering for the repayment of debt, growth of its sales force, progression of its product development and for working capital and general corporate
purposes. The offering is subject to market conditions, and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aegis Capital Corp. is acting as the sole book-running manager for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering is being made pursuant to a shelf registration statement that Precipio previously filed with the Securities and Exchange Commission
(&#147;SEC&#148;) and which became effective on February&nbsp;13, 2015. A preliminary prospectus supplement and accompanying base prospectus relating to the offering have been filed with the SEC and are available on the SEC&#146;s website located at
<U>www.sec.gov</U>. Electronic copies of the preliminary prospectus supplement and accompanying base prospectus may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, NY 10019 or via telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-813-1010</FONT></FONT> or email: <U>prospectus@aegiscap.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Precipio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic
institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale
School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit <U>www.precipiodx.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this
press release constitute &#147;forward-looking statements,&#148; within the meaning of federal securities laws, including statements related to Precipio&#146;s anticipated public offering, anticipated use of proceeds and plans and prospects for
Precipio and other statements containing the words &#147;anticipate,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; and similar
expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company&#146;s actual results could differ materially from those anticipated in these forward-looking statements as a
result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company&#146;s
definitive proxy statement filed on May&nbsp;12, 2017, the Company&#146;s prior filings and from time to time in the Company&#146;s subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties
may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this
information, including any forward-looking statements, unless required by law. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Precipio Investor Relations: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Marco </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Managing Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Core IR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">377 Oak Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garden City, NY 11530 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">516 222 2560 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>johnm@coreir.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.coreir.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d434912dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Overview </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a cancer diagnostics company providing diagnostic products and services to the oncology market. We have built and continue to develop a
platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. We
operate a cancer diagnostic laboratory located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and technologies developed within academia so that we can provide a better standard of
cancer diagnostics and solve the growing problem of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ICE-COLD-PCR,</FONT></FONT> or ICP, the patented technology described further below, which was exclusively licensed by us from Dana-Farber Cancer Institute, Inc., or Dana-Farber, at Harvard University. The research and
development center will focus on the development of this technology, which we believe will enable us to commercialize other technologies developed by our current and future academic partners. Our platform connects patients, physicians and diagnostic
experts residing within academic institutions. Launched in 2017, the platform facilitates the following relationships: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients: patients may search for physicians in their area and consult directly with academic experts that are on the platform. Patients may also have access to new academic discoveries as they become commercially
available. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Physicians: physicians can connect with academic experts to seek consultations on behalf of their patients and may also provide consultations for patients in their area seeking medical expertise in that physician&#146;s
relevant specialty. Physicians will also have access to new diagnostic solutions to help improve diagnostic accuracy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Academic Experts: academic experts on the platform can make themselves available for patients or physicians seeking access to their expertise. Additionally, these experts have a platform available to commercialize their
research discoveries. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to continue updating our platform to allow for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">patient-to-patient</FONT></FONT> communications and allow individuals to share stories and provide support for one another, to allow physicians to consult with their peers to discuss and share challenges and solutions, and
to allow academic experts to interact with others in academia on the platform to discuss their research and cross-collaborate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICP was developed at
Harvard and is licensed exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies, such as blood samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge
of obtaining genetic information on disease progression and changes from sources other than a tumor biopsy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gene sequencing is performed on tissue
biopsies taken surgically from the tumor site in order to identify potential therapies that will be more effective in treating the patient. There are several limitations to this process. First, surgical procedures have several limitations,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cost: surgical procedures are usually performed in a costly hospital environment. For example, according to a recent study the mean cost of lung biopsies is greater than $14,000; surgery also involves hospitalization
and recovery time. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Surgical access: various tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for diagnosis. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Risk: patient health may not permit undergoing an invasive surgery; therefore a biopsy cannot be obtained at all. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Time: the process of scheduling and coordinating a surgical procedure often takes time, delaying the start of patient treatment. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Second, there are several tumor-related limitations that provide a challenge to obtaining such genetic information from a tumor: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Tumors are heterogeneous by nature: a tissue sample from one area of the tumor may not properly represent the tumor&#146;s entire genetic composition; thus, the diagnostic results from a tumor may be incomplete and <FONT
STYLE="white-space:nowrap">non-representative.</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Metastases: in order to accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken from each site (if those sites are even known). These biopsies are very difficult to obtain;
therefore physicians often rely on biopsies taken from the primary tumor site. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The advent of technologies enabling liquid biopsies as an
alternative to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic) shed cells and fragments of DNA into the blood stream. These blood samples are called &#147;liquid biopsies&#148; that contain circulating tumor
DNA, or ctDNA, which hold the same genetic information found in the tumor(s). That tumor DNA is the target of genetic analysis. However, since the quantity of tumor DNA is very small in proportion to the &#147;normal&#148; (or &#147;healthy&#148;)
DNA within the blood stream, there is a need to identify and separate the tumor DNA from the normal DNA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICP is an enrichment technology that enables the
laboratory to focus its analysis on the tumor DNA by enriching, and thereby &#147;multiplying&#148; the presence of, tumor DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory
genetic testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at a higher level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into
a chemical that is provided in the form of a kit and sold to other laboratories who wish to conduct these tests <FONT STYLE="white-space:nowrap">in-house.</FONT> The chemical within the kit is added to the specimen preparation process, enriching the
sample for the tumor DNA so that the analysis will detect those genetic abnormalities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Industry Problem </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently a significant problem with rates of misdiagnosis across numerous disease states (particularly in cancer) due to an
inefficient industry. We believe that the diagnostic industry has been commoditized, focusing primarily on price and test turnaround times as competing factors, at the expense of quality and accuracy. Increasingly complex disease states are met with
eroding specialization rather than increased expertise. According to a study conducted by the National Coalition of Health, this results in an industry with up to 28% cancer misdiagnosis rates which is failing to meet the needs of physicians,
patients and the healthcare system as a whole. New technologies offer improved accuracy; however, many are either inaccessible, or are not economically practical for clinical use. Despite much publicity of the industry transitioning from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-per-service</FONT></FONT> to value-based payments, that transition has not yet occurred in diagnostics. When a patient is misdiagnosed, physicians end up administrating incorrect
treatments, often creating adverse effects rather than improving outcomes, payers waste valuable treatment dollars applied incorrectly and can incur substantial downstream costs and, most importantly, patients pay the ultimate price with increased
morbidity and mortality. According to a report by Pinnacle Health, the estimated cost of misdiagnosis to the healthcare system is $750&nbsp;billion annually. We believe that the academic path of specialization produces the critical expertise
necessary to correctly diagnose disease; and that academic institutions have an unlocked potential to address this problem. Our solution is to create an exclusive platform that harnesses academic expertise and proprietary technologies to deliver the
highest standard of diagnostic accuracy and patient care. Physicians, hospitals, payers and, most importantly, patients all benefit from more accurate diagnostics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Market </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a services and technology commercialization company, we currently participate in two segments within the U.S. domestic oncology diagnostics
market. The first is the anatomic pathology services market, which is estimated to reach $22&nbsp;billion by the end of 2022, growing at an average 8% compound annual growth rate from 2017 to 2021. The second segment is the liquid biopsy
reagents/kits market. According to the Piper Jaffray report from September 2015 on the liquid biopsy market, the domestic market opportunity for the oncology liquid biopsy market is over $28&nbsp;billion per year, and encompasses screening, therapy
selection, treatment monitoring and recurrence. The current market size for new cancer diagnoses is 1.6&nbsp;million new cases per year and over 15.5&nbsp;million people living with cancer, and the cancer diagnostics market size in North America was
estimated to be $50&nbsp;billion in 2016. We believe additional opportunities exist in clinical trials searching for low cost and high quality solutions for patient selection and treatment monitoring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Our Solution </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Platform </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platform is designed to provide physicians and their patients access to the necessary academic expertise and technology to properly
diagnose disease. To our knowledge we are the only company focused on addressing the issue of diagnostic accuracy with an innovative, robust and scalable business model by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Providing physicians and their patients access to world-class academic experts and technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Allowing payers to benefit from quality-based outcomes to their patients and recognize cost savings. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Enabling cross-collaboration between physicians and academic institutions to advance research and discovery. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exclusive agreement with the Department of Pathology at Yale University, or the Pathology Services Agreement, is part of a unique platform
that to our knowledge is not offered by other commercial laboratories. Our customers are oncologists who biopsy their patients in order to confirm or rule out the presence of cancer. After our customers send the samples to us, we conduct all the
technical tests at our New Haven facility. We then transmit the test results to the pathologists at Yale who have access to our laboratory information system from their respective offices, enabling them to review and render their diagnostic
interpretation of the test results, for reporting. In partnership with Yale faculty, we have developed a proprietary algorithm that is applied to each sample submitted to us for testing, resulting in our ability to render a more concise and accurate
diagnosis. The final diagnostic results are prepared by Yale pathologists and integrated into the final report by us, and are then delivered electronically through our web portal to the referring clinician. The patient&#146;s insurance is billed for
the services; we are paid for the technical work done at our laboratory; and Yale pathologists are paid by us for their diagnostic interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently renewed the Pathology Services Agreement for an additional five-year term, effective as of June 2016, through June 2021. Under the
Pathology Services Agreement, the Yale Department of Pathology may not provide the hematopathology services that it provides to us to any other commercial entity that is one of our competitors. The Pathology Services Agreement allows for termination
by either party (i)&nbsp;for uncured breach by the other party, (ii)&nbsp;if either party has its respective license suspended or revoked, (iii)&nbsp;if the insurance coverage of either party is canceled or modified, (iv)&nbsp;if we fail to maintain
or meet the requirements of Medicare conditions of participation, or (v)&nbsp;if we declare bankruptcy. The Pathology Services Agreement also provides that if the performance by either party (i)&nbsp;jeopardizes the licensure or accreditation of
Yale or any Yale physician, (ii)&nbsp;jeopardizes either party&#146;s participation in Medicare, Medicaid or other federal, state or commercial reimbursement programs, (iii)&nbsp;violates any statute, ordinance or otherwise is deemed illegal,
(iv)&nbsp;is deemed unethical by any recognized body, agency or association in the medical or laboratory fields, or (v)&nbsp;causes a substantial threat to Yale&#146;s <FONT STYLE="white-space:nowrap">tax-exempt</FONT> status, then either party may
initiate negotiations to amend the Pathology Services Agreement and the Pathology Services Agreement will terminate if a mutually agreed amendment is not executed by the parties within 30 days. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ICE-COLD-PCR</FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ICP technology was developed at Dana-Farber and is licensed by us. ICP is a unique, proprietary patented specimen enrichment technology that
increases the sensitivity of molecular based tests from approximately <FONT STYLE="white-space:nowrap">90-95%</FONT> to <FONT STYLE="white-space:nowrap">99-99.99%.</FONT> Traditional molecular testing is done on tumor biopsies. These tests are
typically conducted at disease onset, when the patient undergoes a biopsy. In the typical course of treatment, a patient is rarely <FONT STYLE="white-space:nowrap">re-biopsied,</FONT> and therefore the only genetic information is based on the
initial biopsy. Tumors are known to shed cells into the patient&#146;s blood stream, where they circulate alongside normal cells; however, existing testing methodologies are not sufficiently sensitive to differentiate between the tumor and normal
cells. The increased sensitivity provided by ICP allows for testing of genetic mutations that occur within tumors to be conducted on peripheral blood samples, termed liquid biopsies. This technical capability enables physicians to test for genetic
mutations without conducting a biopsy, through a simple blood test rather than a biopsy extracted from the actual tumor. The results of such tests can be used for diagnosis, prognosis and therapeutic decisions. The technology is encapsulated within
a chemical (reagent) used during the specimen preparation process, which enriches (amplifies) the tumor DNA detected within the blood sample, while suppressing the normal DNA. In addition to offering this technology as a clinical service, we are
developing panels that will be sold as reagent kits to other laboratories to set up this testing in their facilities. This enables other labs to improve their test sensitivity and render results on liquid biopsies. The business model of selling
reagents to other laboratories both expands the reach and impact of the technology, while eliminating the reimbursement risks that we would face in running the tests <FONT STYLE="white-space:nowrap">in-house.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We license the ICP technology from Dana-Farber through a license agreement, or the License Agreement. The License Agreement grants us an
exclusive license to the ICP technology, subject to a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license granted to the U.S. government, in the areas of mutation detection using Sanger <FONT STYLE="white-space:nowrap">(di-deoxy)</FONT>
sequencing and mitochondrial DNA analysis for all research, diagnostic, prognostic and therapeutic uses in humans, animals, viruses, bacteria, fungi, plants or fossilized material. The License Agreement also grants us a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license in the areas of mutation detection using DHPLC, surveyor-endonuclease-based mutation detection and second generation sequencing techniques. We paid Dana-Farber an initial license fee and are
required to make milestone payments with respect to the first five licensed products or services we develop using the licensed technology as well as royalties ranging from high single to low double digits on net sales of licensed products and
services for sales made by us and sales made to any distributors. The License Agreement remains in effect until we cease to sell licensed products or services under the agreement. Dana-Farber has the right to immediately terminate the License
Agreement if (i)&nbsp;we cease to carry on our business with respect to licensed products and services, (ii)&nbsp;we fail to make any payments under the License Agreement (subject to a cure period), (iii) we fail to comply with due diligence
obligations under the License Agreement (subject to a cure period), (iv) we default in our obligations to procure and maintain insurance as required by the License Agreement, (v)&nbsp;any of our officers is convicted of a felony relating to the
manufacture, use, sale or importation of licensed products under the License Agreement, (vi)&nbsp;we materially breach any provision of the License Agreement (subject to a cure period), or (vii)&nbsp;we or Dana-Farber become insolvent. We may
terminate the License Agreement for convenience upon 180 days&#146; prior written notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since cancer is typically a disease with an onset at a later age, the largest insurance provider which constitutes close to 32% of our patient
cases is Medicare. The remaining patients are insured by private insurance companies who provide patient coverage and pay for patients health-related costs. The Center for Medicare and Medicaid Services, or CMS, typically publishes its rates
annually, and providers such as us bill according to the codes relevant to the tests we conduct. Other private insurance companies will often follow suit and adjust their rates according to the published CMS rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Our Products </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial product
offering consists of clinical diagnostic services harnessing the expertise of the Yale School of Medicine and the commercialization and application of ICP, a cutting-edge technology developed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at Dana-Farber, part of Harvard University. Our clinical diagnostic services focus on the diagnosis of blood cancers and the delivery of an accurate diagnosis to oncologists, with demonstrated
superior results through an exclusive partnership with Yale. We intend to enter into additional partnerships during 2017 and 2018. Our cutting-edge liquid biopsy technology, ICP, enables detection of abnormalities in blood samples (cfDNA) down to as
low as .01%. This <FONT STYLE="white-space:nowrap">low-cost</FONT> technology enables customers to conduct the tests <FONT STYLE="white-space:nowrap">in-house</FONT> using existing mutation detection platforms and creates what we believe to be the
only current economically viable option for liquid biopsy applications. Our customers are oncologists, hospitals, reference laboratories, and pharma and biotech companies, to whom we plan to cross-market other technologies (such as ICP) and services
on our platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We built and obtained CLIA certification to operate our New Haven laboratory. The laboratory is approximately 3,000
square feet and has several <FONT STYLE="white-space:nowrap">sub-departments</FONT> such as flow cytometry, immune-histochemistry, cytogenetics, and molecular testing. The laboratory is currently operated by five lab technicians and is supervised by
a laboratory manager and a medical director. Our laboratory is inspected every two years by a Connecticut state-appointed inspection, and once approved by the state inspector, we are issued a CLIA-certificate. Furthermore, the laboratory supervisor
and medical director must conduct a self-inspection every two years (rotating with the state inspection) and must submit those results to the state department of health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laboratory operations are governed by Standard Operating Procedure manuals, or SOPs, which detail each aspect of the laboratory
environment including the work flow, quality control, maintenance, and safety. These SOPs are reviewed annually, approved and signed off by the laboratory manager and medical director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Our Strategy </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our objective is to
eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. To achieve this objective
our strategy is to focus our efforts on the following areas: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Clinical pathology services</B> &#150; we intend to continue building our platform by increasing the number of academic experts available on our platform and partnering with other academic institutions, allowing us
to expand our portfolio of services to cover additional types of cancer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><FONT STYLE="white-space:nowrap">Ice-Cold</FONT> PCR</B> &#150; we believe we can commercialize and develop new applications for our ICP technology, including: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Developing specific application panels for patient monitoring for treatment resistance and disease recurrence; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Building focused diagnostic and screening panels for initial disease identification; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Leveraging our platform customers to generate demand for repeat, localized, <FONT STYLE="white-space:nowrap">in-house</FONT> liquid biopsy testing; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Applying ICP technology to other markets, such as <FONT STYLE="white-space:nowrap">pre-natal</FONT> and companion diagnostics. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>New product pipeline through outsourced research and development</B> &#150; we plan on utilizing our partnerships with academic institutions to gain access to newly-developed technologies. We also believe there is an
opportunity to partner with biotechnology companies to introduce their products to the U.S. market through our platform. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Academic partnerships</B> &#150; we intend to leverage the intellectual expertise and technologies developed within academic institutions. We believe we have validated this model through our partnership with the Yale
School of Medicine and are currently in the process of adding new academic partners. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Competition </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal competition in clinical pathology services comes largely from two groups. The first group consists of companies that specialize
in oncology and offer directly competing services to our diagnostic services. These companies often provide a high level of service focused on oncology and offer their services to oncologists and pathology departments within hospitals. Our
competitors in this group include Genoptix, GenPath Diagnostics and Miraca Life Sciences. The second group consists of large commercial companies that offer a wide variety of laboratory tests ranging from simple chemistry tests to complex genetic
testing. Our competitors in this group include LabCorp and Quest Diagnostics. We believe that companies in this industry primarily compete on price and speed results delivery. We have chosen to focus on the quality and accuracy of results. Within
the liquid biopsy market, our competitors include Guardant Health and Trovagene, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><U>Competitive Advantage </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We capitalize on the intellectual expertise and technologies developed within academic institutions by academic experts. While several industry
papers report a misdiagnosis rate as high as 28% of cases diagnosed, we believe that leveraging academic expertise in diagnosis can significantly reduce the number of patients being misdiagnosed. In an initial data set of over 100 clinical cases
received and processed by us with a diagnosis rendered by Yale pathologists, we believe less than 1% have resulted in misdiagnosis. The diagnostic report provided by us was then requested by a patient or the patient&#146;s physician for a second
opinion to be conducted by another laboratory. In those cases, less than 1% reported back a disagreement with the original primary diagnosis. While a minority of patients are treated in academic centers and can benefit from that specialized
expertise, the majority of patients are diagnosed by commercial reference laboratories. Comparatively, these commercial laboratories and diagnostic companies have broad access to and serve a majority of patients; however, we believe their lack of
specialized expertise results in significantly higher misdiagnosis rates. Academic institutions also invest heavily in the development of new technologies, many of which are often used only within the academic institution and do not benefit outside
patients. Our platform offers patients anywhere access to these innovative technologies developed within Yale and any other academic institutions we engage in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, after receiving approval from the Yale Human Investigation Committee, we commenced a study to demonstrate the impact of academic
pathology expertise on diagnostic accuracy. The purpose of this study is to use data from a large set of patients to determine whether academic pathologists provide a higher level of accuracy of the diagnosis, improving patient care, as well as
reducing the subsequent costs involved in treating the patient, compared to diagnosis conducted outside of an academic institution. The study is being conducted at the Department of Pathology at Yale School of Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The retrospective study will gather data on approximately 500 to 1,000 patients who have received an initial diagnosis, followed by a second
opinion, and stratify them into two cohorts. The first cohort will consist of patients diagnosed initially outside of an academic institution, and then referred to Yale for treatment where they received a second opinion diagnosis by an academic
pathologist at Yale. The second cohort will consist of patients initially diagnosed at Yale, who then proceeded to obtain a second opinion from an outside institution. The study will identify those patients where the second opinion differs from the
initial diagnosis, suggesting a possible misdiagnosis. In those situations, the case will be referred to another academic institution to conduct a blinded, third evaluation in order to determine which diagnosis was correct. The study will then
further evaluate the subsequent patient response due to the change in diagnosis, to determine the impact that the change in diagnosis had on the patient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the study, we have also partnered with the Department of Medicine at Thomas Jefferson University in Philadelphia, which routinely
conducts research to evaluate the economic impact of various healthcare decisions, to quantify the cost of misdiagnosis within cancer treatment. In those situations where discordance is identified between the primary and secondary diagnosis, an
evaluation will be made of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pre-and-post</FONT></FONT> diagnosis change in the course of treatment, to correlate both the healthcare dollars spent, and the clinical outcome. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g434912g0731133059618.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g434912g0731133059618.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- 9,# 2(  A$! Q$!_\0
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MHQ)! /;BLK_A6'A'_H%+_P!_&_QKKZ*A3DE9,+(Y#_A6'A'_ *!2_P#?QO\
M&HKCX5^$YH2B6#0L>CQR-D?K7:44_:3[A9'D<+ZG\+O$5K;7%U)=^';U]BLY
MYB/]"/U%>LO@Q,<Y!6N ^,C0CP2J/CSFND\H=\\Y_2NTTU9%T.T67/F"V0/G
MKG:,U4_>BI=06]CRCX:>%-%U_3M3FU.Q2>2*\9$))X&,XKN?^%:^$O\ H$1_
M]]&L#X-?\@?6/^O]OY"O2Z=6<E-V8DE8Y/\ X5KX2_Z!$?\ WT:/^%:^$O\
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MHP2?G:L8J*CS,T=[E'_A;_A__GC>_P#?DT?\+?\ #_\ SQO?^_1KN/[.L?\
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M$4^_L+G3+^>QNXS'<0.4=3Z_X56KTMS$^F?"'BZR\5:4D\3*EV@ G@)Y1O\
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MCW_H3I/U_P *TJ0<I-H2>AZ917F?_"8^/?\ H3I/U_PH_P"$Q\>_]"=)^O\
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@- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
